FDA proposes naming system for biosimilars

Draft guidance from the FDA on the naming of biosimilars recommends the generic name is retained with four random letters added at the end to provide a unique identifier. “Our current thinking is that shared nonproprietary names are not appropriate for all biological products,” the FDA said in a statement. “There is a need to clearly ...

Already a member?

Login to keep reading.

© 2021 the limbic